Signatera
1 product
6 abstracts
Abstract
Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS).Org: Princess Margaret Cancer Centre, Department of Pathology and Laboratory Medicine, Radiation Medicine Program, Natera, Inc., University Health Network,
Abstract
Evaluation of genomic alterations in early-onset versus late-onset colorectal cancer.Org: Natera, Inc., Natera, Inc, Vanderbilt-Ingram Cancer Center,
Abstract
Longitudinal circulating tumor DNA monitoring in patients with esophageal squamous cell carcinoma.Org: Department of gastroenterology and gastrointestinal oncology, National Cancer Center Hospital East, Kashiwa, Japan, Division of Esophageal Surgery, National Cancer Center Hospital East, Kashiwa, Japan, Natera, Inc., Austin, TX, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.Org: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, MD Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors.Org: Indiana University – Purdue University Indianapolis, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indianapolis, IN, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center,
Abstract
Detection of ctDNA in patients with stage III cutaneous melanoma with satellite/in-transit or nodal metastases.Org: Inova Schar Cancer Institute, Fairfax, VA,
Product
Signatera